UK markets closed

BioInvent International AB (publ) (0H22.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
44.540.00 (0.00%)
At close: 04:13PM GMT
Full screen
Previous close44.54
Open44.54
Bid0.00 x N/A
Ask0.00 x N/A
Day's range44.54 - 44.54
52-week range44.54 - 44.54
Volume220
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Transgene and BioInvent Joint Paper on BT-001 Wins JITC "Best Oncolytic and Local Immunotherapy Paper" Award for 2022

    STRASBOURG, France, November 14, 2022--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced that a paper co-authored by researchers from Transgene and BioInvent is the rec

  • Business Wire

    Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

    ALAMEDA, Calif. & LUND, Sweden, June 16, 2022--Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics. The collaboration is intended to expand Exelixis’ portfolio of antibody-based therapies and will combine BioInvent’s cancer immunology and antibody biology expertise with Exe